{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:47:14Z","timestamp":1787021234781,"version":"build-2736575974"},"reference-count":70,"publisher":"The Endocrine Society","issue":"11","funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF14OC0009315"],"award-info":[{"award-number":["NNF14OC0009315"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF13OC0003882"],"award-info":[{"award-number":["NNF13OC0003882"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Danish Council for Independent Research","doi-asserted-by":"crossref","award":["DFF 4004-00235"],"award-info":[{"award-number":["DFF 4004-00235"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Augmenting nicotinamide adenine dinucleotide (NAD+) metabolism through dietary provision of NAD+ precursor vitamins translates to improved glucose handling in rodent models of obesity and diabetes. Preclinical evidence suggests that the NAD+\/SIRT1 axis may be implicated in modulating important gut-related aspects of glucose regulation. We sought to test whether NAD+ precursor supplementation with nicotinamide riboside (NR) affects \u03b2-cell function, \u03b1-cell function, and incretin hormone secretion as well as circulating bile acid levels in humans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A 12-week randomized, double-blind, placebo-controlled, parallel-group trial in 40 males with obesity and insulin resistance allocated to NR at 1000 mg twice daily (n = 20) or placebo (n = 20). Two-hour 75-g oral glucose tolerance tests were performed before and after the intervention, and plasma concentrations of glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were determined. \u03b2-Cell function indices were calculated based on glucose, insulin, and C-peptide measurements. Fasting plasma concentrations of bile acids were determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>NR supplementation during 12 weeks did not affect fasting or postglucose challenge concentrations of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and \u03b2-cell function did not respond to the intervention. Additionally, no changes in circulating adipsin or bile acids were observed following NR supplementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The current study does not provide evidence to support that dietary supplementation with the NAD+ precursor NR serves to impact glucose tolerance, \u03b2-cell secretory capacity, \u03b1-cell function, and incretin hormone secretion in nondiabetic males with obesity. Moreover, bile acid levels in plasma did not change in response to NR supplementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jc.2019-01081","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T09:04:53Z","timestamp":1565168693000},"page":"5703-5714","source":"Crossref","is-referenced-by-count":73,"title":["Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity"],"prefix":"10.1210","volume":"104","author":[{"given":"Ole L","family":"Dollerup","sequence":"first","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Medical Research Laboratory, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A J","family":"Trammell","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolette","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Biomedical Sciences, Section for Translational Metabolic Physiology, University of Copenhagen, Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens J","family":"Holst","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Biomedical Sciences, Section for Translational Metabolic Physiology, University of Copenhagen, Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt","family":"Christensen","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Medical Research Laboratory, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"Medical Research Laboratory, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P","family":"Gillum","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1488-7012","authenticated-orcid":false,"given":"Jonas T","family":"Treebak","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5613-7274","authenticated-orcid":false,"given":"Niels","family":"Jessen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Biomedicine, Aarhus University, Aarhus, Denmark"},{"name":"Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"issue":"7121","key":"2019101203584515100_bib1","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/nature05482","article-title":"Mechanisms linking obesity to insulin resistance and type 2 diabetes","volume":"444","author":"Kahn","year":"2006","journal-title":"Nature"},{"issue":"3","key":"2019101203584515100_bib2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3945\/an.113.005488","article-title":"Pancreatic \u03b2-cell proliferation in obesity","volume":"5","author":"Linnemann","year":"2014","journal-title":"Adv Nutr"},{"key":"2019101203584515100_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fendo.2013.00037","article-title":"Beta cell dysfunction and insulin resistance","volume":"4","author":"Cerf","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2019101203584515100_bib4","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1152\/ajpendo.00545.2003","article-title":"Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans","volume":"287","author":"Holst","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"2019101203584515100_bib5","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1463-1326.2011.01549.x","article-title":"Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity","volume":"14","author":"Knop","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2019101203584515100_bib6","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.2337\/dc11-s227","article-title":"Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes","volume":"34","author":"Holst","year":"2011","journal-title":"Diabetes Care"},{"issue":"7","key":"2019101203584515100_bib7","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.2337\/db14-1751","article-title":"GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study","volume":"64","author":"F\u00e6rch","year":"2015","journal-title":"Diabetes"},{"issue":"3","key":"2019101203584515100_bib8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00125-007-0899-2","article-title":"Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and\/or impaired glucose tolerance in the EUGENE2 study","volume":"51","author":"Laakso","year":"2008","journal-title":"Diabetologia"},{"issue":"5","key":"2019101203584515100_bib9","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2337\/db07-1315","article-title":"Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients","volume":"57","author":"Muscelli","year":"2008","journal-title":"Diabetes"},{"issue":"3","key":"2019101203584515100_bib10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2337\/db07-1124","article-title":"Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance","volume":"57","author":"Vollmer","year":"2008","journal-title":"Diabetes"},{"issue":"9","key":"2019101203584515100_bib11","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.metabol.2005.03.024","article-title":"Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus","volume":"54","author":"Henkel","year":"2005","journal-title":"Metabolism"},{"issue":"3","key":"2019101203584515100_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.cmet.2017.11.002","article-title":"NAD+ intermediates: the biology and therapeutic potential of NMN and NR","volume":"27","author":"Yoshino","year":"2018","journal-title":"Cell Metab"},{"issue":"3","key":"2019101203584515100_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cmet.2018.02.011","article-title":"Therapeutic potential of NAD-boosting molecules: the in vivo evidence","volume":"27","author":"Rajman","year":"2018","journal-title":"Cell Metab"},{"issue":"6","key":"2019101203584515100_bib14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cmet.2012.04.022","article-title":"The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity","volume":"15","author":"Cant\u00f3","year":"2012","journal-title":"Cell Metab"},{"issue":"4","key":"2019101203584515100_bib15","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.28245","article-title":"Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice","volume":"63","author":"Gariani","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"2019101203584515100_bib16","doi-asserted-by":"crossref","first-page":"26933","DOI":"10.1038\/srep26933","article-title":"Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice","volume":"6","author":"Trammell","year":"2016","journal-title":"Sci Rep"},{"issue":"15","key":"2019101203584515100_bib17","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1111\/bph.13513","article-title":"Hepatic NAD+ deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing","volume":"173","author":"Zhou","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2019101203584515100_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev.pathol.4.110807.092250","article-title":"Mammalian sirtuins: biological insights and disease relevance","volume":"5","author":"Haigis","year":"2010","journal-title":"Annu Rev Pathol"},{"key":"2019101203584515100_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/dom.12171","article-title":"The importance of NAMPT\/NAD\/SIRT1 in the systemic regulation of metabolism and ageing","volume":"15","author":"Imai","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2019101203584515100_bib20","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1152\/physrev.00022.2011","article-title":"Sirtuin 1 and sirtuin 3: physiological modulators of metabolism","volume":"92","author":"Nogueiras","year":"2012","journal-title":"Physiol Rev"},{"issue":"8","key":"2019101203584515100_bib21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1517\/14728222.2012.703656","article-title":"Can targeting SIRT-1 to treat type 2 diabetes be a good strategy? A review","volume":"16","author":"Pulla","year":"2012","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"2019101203584515100_bib22","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1371\/journal.pbio.0040031","article-title":"Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic \u03b2 cells [published correction appears in PLoS Biol. 2006;4(9):e295]","volume":"4","author":"Bordone","year":"2006","journal-title":"PLoS Biol"},{"issue":"9","key":"2019101203584515100_bib23","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s00125-013-2946-5","article-title":"The loss of Sirt1 in mouse pancreatic beta cells impairs insulin secretion by disrupting glucose sensing","volume":"56","author":"Luu","year":"2013","journal-title":"Diabetologia"},{"issue":"6","key":"2019101203584515100_bib24","doi-asserted-by":"crossref","first-page":"e0128012","DOI":"10.1371\/journal.pone.0128012","article-title":"Pancreas-specific Sirt1-deficiency in mice compromises beta-cell function without development of hyperglycemia","volume":"10","author":"Pinho","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"2019101203584515100_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2337\/db07-1795","article-title":"Overexpression of SIRT1 protects pancreatic \u03b2-cells against cytokine toxicity by suppressing the nuclear factor-\u03baB signaling pathway","volume":"58","author":"Lee","year":"2009","journal-title":"Diabetes"},{"issue":"2","key":"2019101203584515100_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cmet.2005.07.001","article-title":"Increased dosage of mammalian Sir2 in pancreatic \u03b2 cells enhances glucose-stimulated insulin secretion in mice","volume":"2","author":"Moynihan","year":"2005","journal-title":"Cell Metab"},{"issue":"5","key":"2019101203584515100_bib27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cmet.2007.09.003","article-title":"Nampt\/PBEF\/visfatin regulates insulin secretion in \u03b2 cells as a systemic NAD biosynthetic enzyme","volume":"6","author":"Revollo","year":"2007","journal-title":"Cell Metab"},{"issue":"1","key":"2019101203584515100_bib28","doi-asserted-by":"crossref","first-page":"13103","DOI":"10.1038\/ncomms13103","article-title":"NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells","volume":"7","author":"Ratajczak","year":"2016","journal-title":"Nat Commun"},{"issue":"12","key":"2019101203584515100_bib29","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1007\/s00125-011-2288-0","article-title":"Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function","volume":"54","author":"Caton","year":"2011","journal-title":"Diabetologia"},{"issue":"4","key":"2019101203584515100_bib30","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cmet.2011.08.014","article-title":"Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice","volume":"14","author":"Yoshino","year":"2011","journal-title":"Cell Metab"},{"issue":"1","key":"2019101203584515100_bib31","doi-asserted-by":"crossref","first-page":"e54106","DOI":"10.1371\/journal.pone.0054106","article-title":"The adipocytokine Nampt and its product NMN have no effect on beta-cell survival but potentiate glucose stimulated insulin secretion","volume":"8","author":"Spinnler","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"2019101203584515100_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cell.2014.06.005","article-title":"Adipsin is an adipokine that improves \u03b2 cell function in diabetes","volume":"158","author":"Lo","year":"2014","journal-title":"Cell"},{"issue":"7","key":"2019101203584515100_bib33","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.celrep.2016.07.027","article-title":"NAMPT-mediated NAD+ biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice","volume":"16","author":"Stromsdorfer","year":"2016","journal-title":"Cell Reports"},{"issue":"17","key":"2019101203584515100_bib34","doi-asserted-by":"crossref","first-page":"17187","DOI":"10.1074\/jbc.M501250200","article-title":"Mechanism of human SIRT1 activation by resveratrol","volume":"280","author":"Borra","year":"2005","journal-title":"J Biol Chem"},{"issue":"6","key":"2019101203584515100_bib35","doi-asserted-by":"crossref","first-page":"e20700","DOI":"10.1371\/journal.pone.0020700","article-title":"Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control","volume":"6","author":"Dao","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"2019101203584515100_bib36","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/dme.12231","article-title":"Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects","volume":"30","author":"Knop","year":"2013","journal-title":"Diabet Med"},{"issue":"1","key":"2019101203584515100_bib37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3945\/ajcn.115.117440","article-title":"Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial","volume":"103","author":"Thazhath","year":"2016","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"2019101203584515100_bib38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","article-title":"Pleiotropic roles of bile acids in metabolism","volume":"17","author":"de Aguiar Vallim","year":"2013","journal-title":"Cell Metab"},{"issue":"7","key":"2019101203584515100_bib39","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease","volume":"152","author":"Ch\u00e1vez-Talavera","year":"2017","journal-title":"Gastroenterology"},{"issue":"7","key":"2019101203584515100_bib40","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1128\/MCB.05988-11","article-title":"Hepatic deletion of SIRT1 decreases hepatocyte nuclear factor 1\u03b1\/farnesoid X receptor signaling and induces formation of cholesterol gallstones in mice","volume":"32","author":"Purushotham","year":"2012","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2019101203584515100_bib41","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1053\/j.gastro.2013.12.029","article-title":"Intestine-specific deletion of SIRT1 in mice impairs DCoH2\u2013HNF-1\u03b1\u2013FXR signaling and alters systemic bile acid homeostasis","volume":"146","author":"Kazgan","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"2019101203584515100_bib42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bbamcr.2016.10.020","article-title":"Metformin impairs systemic bile acid homeostasis through regulating SIRT1 protein levels","volume":"1864","author":"Chen","year":"2017","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"5","key":"2019101203584515100_bib43","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cmet.2009.09.009","article-title":"FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states","volume":"10","author":"Kemper","year":"2009","journal-title":"Cell Metab"},{"issue":"2","key":"2019101203584515100_bib44","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ajcn\/nqy132","article-title":"A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects","volume":"108","author":"Dollerup","year":"2018","journal-title":"Am J Clin Nutr"},{"key":"2019101203584515100_bib45","volume-title":"Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO\/IDF Consultation","author":"World Health Organization","year":"2006"},{"issue":"4","key":"2019101203584515100_bib46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diab.43.4.535","article-title":"Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans","volume":"43","author":"Orskov","year":"1994","journal-title":"Diabetes"},{"issue":"8","key":"2019101203584515100_bib47","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1210\/jc.2011-0266","article-title":"Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans","volume":"96","author":"Lindgren","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019101203584515100_bib48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI115012","article-title":"Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine","volume":"87","author":"Orskov","year":"1991","journal-title":"J Clin Invest"},{"issue":"15","key":"2019101203584515100_bib49","doi-asserted-by":"crossref","first-page":"122737","DOI":"10.1172\/jci.insight.122737","article-title":"Divergent effects of resistance and endurance exercise on plasma bile acids, FGF19, and FGF21 in humans","volume":"3","author":"Morville","year":"2018","journal-title":"JCI Insight"},{"issue":"7","key":"2019101203584515100_bib50","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"issue":"3","key":"2019101203584515100_bib51","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00125-016-4165-3","article-title":"Discriminatory ability of simple OGTT-based beta cell function indices for prediction of prediabetes and type 2 diabetes: the CODAM study","volume":"60","author":"den Biggelaar","year":"2017","journal-title":"Diabetologia"},{"issue":"3","key":"2019101203584515100_bib52","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1464-5491.1994.tb00273.x","article-title":"Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion","volume":"11","author":"Phillips","year":"1994","journal-title":"Diabet Med"},{"issue":"2","key":"2019101203584515100_bib53","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2337\/dc08-1478","article-title":"Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels [published correction appears in Diabetes Care. 2009;32(7):1355]","volume":"32","author":"Utzschneider","year":"2009","journal-title":"Diabetes Care"},{"issue":"3","key":"2019101203584515100_bib54","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.diabres.2005.10.005","article-title":"Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT","volume":"72","author":"Tura","year":"2006","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2019101203584515100_bib55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s42255-018-0009-4","article-title":"Bruzzone S, Sociali G, Tokizane K, Lei HC, Cunningham R, Sasaki Y, Migaud ME, Imai SI. Slc12a8 is a nicotinamide mononucleotide transporter","volume":"1","author":"Grozio","year":"2019","journal-title":"Nat Metab"},{"issue":"13","key":"2019101203584515100_bib56","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1074\/jbc.C800021200","article-title":"Saccharomyces cerevisiae YOR071C encodes the high affinity nicotinamide riboside transporter Nrt1","volume":"283","author":"Belenky","year":"2008","journal-title":"J Biol Chem"},{"issue":"24","key":"2019101203584515100_bib57","doi-asserted-by":"crossref","first-page":"21767","DOI":"10.1074\/jbc.M110.213298","article-title":"Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation","volume":"286","author":"Nikiforov","year":"2011","journal-title":"J Biol Chem"},{"issue":"1","key":"2019101203584515100_bib58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15257770.2016.1210805","article-title":"Equilibrative nucleoside transporters\u2014a review","volume":"36","author":"Boswell-Casteel","year":"2017","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"9413","key":"2019101203584515100_bib59","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0140-6736(04)15786-3","article-title":"European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes","volume":"363","author":"Gale","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"2019101203584515100_bib60","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.molcel.2005.02.022","article-title":"Mechanism of sirtuin inhibition by nicotinamide: altering the NAD+ cosubstrate specificity of a Sir2 enzyme","volume":"17","author":"Avalos","year":"2005","journal-title":"Mol Cell"},{"issue":"1","key":"2019101203584515100_bib61","doi-asserted-by":"crossref","first-page":"12948","DOI":"10.1038\/ncomms12948","article-title":"Nicotinamide riboside is uniquely and orally bioavailable in mice and humans","volume":"7","author":"Trammell","year":"2016","journal-title":"Nat Commun"},{"issue":"12","key":"2019101203584515100_bib62","doi-asserted-by":"crossref","first-page":"e0186459","DOI":"10.1371\/journal.pone.0186459","article-title":"An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers","volume":"12","author":"Airhart","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"2019101203584515100_bib63","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41467-018-03421-7","article-title":"Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults","volume":"9","author":"Martens","year":"2018","journal-title":"Nat Commun"},{"issue":"8","key":"2019101203584515100_bib64","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1007\/s00125-014-3264-2","article-title":"Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals","volume":"57","author":"Bagger","year":"2014","journal-title":"Diabetologia"},{"issue":"5","key":"2019101203584515100_bib65","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/jdi.12819","article-title":"Relationship between serum adipsin and the first phase of glucose-stimulated insulin secretion in individuals with different glucose tolerance","volume":"9","author":"Zhou","year":"2018","journal-title":"J Diabetes Investig"},{"issue":"2","key":"2019101203584515100_bib66","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","article-title":"Bile salt biotransformations by human intestinal bacteria","volume":"47","author":"Ridlon","year":"2006","journal-title":"J Lipid Res"},{"issue":"3","key":"2019101203584515100_bib67","doi-asserted-by":"crossref","first-page":"e12935","DOI":"10.1111\/acel.12935","article-title":"NAD+ supplementation rejuvenates aged gut adult stem cells","volume":"18","author":"Igarashi","year":"2019","journal-title":"Aging Cell"},{"key":"2019101203584515100_bib68","volume-title":"Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline","author":"Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and Its Panel on Folate, Other B Vitamins, and Choline","year":"1998"},{"issue":"1","key":"2019101203584515100_bib69","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1573399810666140214093600","article-title":"Assessment of pancreatic \u03b2-cell function: review of methods and clinical applications","volume":"10","author":"Cersosimo","year":"2014","journal-title":"Curr Diabetes Rev"},{"issue":"1","key":"2019101203584515100_bib70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41514-017-0016-9","article-title":"Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study [published correction appears in NPJ Aging Mech Dis.2018;4:8]","volume":"3","author":"Dellinger","year":"2017","journal-title":"NPJ Aging Mech Dis"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/jc.2019-01081\/29104943\/jc.2019-01081.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/11\/5703\/30137818\/jc.2019-01081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/11\/5703\/30137818\/jc.2019-01081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T04:00:10Z","timestamp":1570852810000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/11\/5703\/5544497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2019-01081","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,8,7]]}}}